Thyroid cytology smear slides: An untapped resource for ThyroSeq testing
Цитологические мазки щитовидной железы: неиспользованный ресурс для тестирования ThyroSeq
2020-07-22
SCID: 54.1/jjbmafpw
Discuss with AI
BRAF mutationThyroSeq Genomic Classifiercytology smear slidesmolecular alteration detectionthyroid FNA cytology
Figures from the paper
Abstract (AI)
BACKGROUND: Molecular testing of thyroid nodules with indeterminate fine-needle aspiration (FNA) cytology is commonly used to guide patient management and is typically performed on freshly collected FNA samples. In this study, the authors evaluated the performance of the ThyroSeq test in cytology smear slides. METHODS: Air-dried Diff-Quik (DQ)-stained and alcohol-fixed Papanicolaou (Pap)-stained smears were used to determine required cellularity and sensitivity of mutation detection and to compare ThyroSeq v3 Genomic Classifier (GC) results obtained in cytology smears and fresh FNA samples from the same nodules. RESULTS: ThyroSeq testing of 31 cytology smears revealed that 25 smears (81%) were adequate for ThyroSeq analysis, including 14 Pap-stained smears (100%) and 11 DQ-stained smears (65%), whereas 6 DQ-stained smears (35%) failed RNA sequencing. The overall accuracy for detecting molecular alterations was 98%, with 100% concordance for mutations and gene expression alterations, 96% concordance for fusions, and 94% concordance for copy number alterations. Cytology smears were adequate for ThyroSeq analysis when at least 200 to 300 cells were present in 1 to 3 slides. ThyroSeq detected all studied mutations down to 5% allele frequency and BRAF mutations down to 1% allele frequency. Testing of smears yielded a positive ThyroSeq GC result in all nodules originally classified as positive. CONCLUSIONS: Thyroid FNA cytology smear slides with adequate cellularity can be successfully used for ThyroSeq GC testing in approximately 80% of cases, with an even higher success rate in Pap-stained smears. Compared with FNA samples collected into preservative solution, 94% to 100% of different genetic alterations could be accurately detected in smears, validating cytology smears as an alternative for ThyroSeq testing in patients with indeterminate thyroid cytology.
Key Findings
1
At least 200–300 cells distributed across 1–3 slides were sufficient for ThyroSeq analysis.
2
Cytology smears produced positive ThyroSeq genomic classifier results for all nodules originally classified as positive, supporting smears as an alternative to fresh FNA samples.
3
Overall detection accuracy for molecular alterations was 98%, with 100% concordance for mutations and gene-expression alterations, 96% for fusions, and 94% for copy-number alterations.
4
ThyroSeq detected all studied mutations at allele frequencies down to 5% and detected BRAF mutations down to 1%.
5
ThyroSeq testing was successful in approximately 80% of thyroid cytology smears with adequate cellularity, including 100% of Pap-stained and 65% of Diff-Quik-stained smears.
Research Object
Thyroid fine-needle aspiration cytology smear slides, including air-dried Diff-Quik- and alcohol-fixed Papanicolaou-stained smears from indeterminate thyroid nodules
Research Subject
Performance of ThyroSeq v3 Genomic Classifier testing in cytology smears, including cellularity requirements, sensitivity, adequacy, and concordance in detecting mutations, gene fusions, gene-expression alterations, and copy-number alterations compared with fresh FNA samples
Publication Details
Publication Date
2020-07-22
Journal
Publisher
ISSN
Cited by
43
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest
References available in scid.ai2
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer2015
Analytical performance of the ThyroSeq v3 genomic classifier for cancer diagnosis in thyroid nodules2018